Compare Marathon Digital Holdings Inc (MARA) vs TG Therapeutics Inc (TGTX) Price & Performance

Marathon Digital Holdings (MARA) trades at $9.65, down 6.85% in the last session, reflecting ongoing volatility. The stock shows mixed signals with bearish technical indicators but positive analyst sentiment. Recent earnings have consistently missed expectations, with Q2 2026 EPS of -$1.60 versus expected $0.17. Despite negative profitability metrics, the company maintains strong analyst coverage with a consensus price target of $13.25, suggesting 37% upside potential from current levels.

MARA presents a high-risk opportunity with significant divergence between fundamental performance and market expectations. While valuation ratios appear attractive (P/E 3.37, EV/EBITDA 3.31), persistent negative earnings and cash flow challenges create substantial execution risk. The stock's performance remains heavily dependent on broader market sentiment and the company's ability to improve operational efficiency amid competitive pressures.

TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.

The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.